Roche drug shows superior efficacy in lung cancer study
By United One News · AI-generated summary of 3 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Roche announced pivotal phase III trial results in Basel on October 25, 2026, showing divarasib improved survival in pre-treated lung cancer patients.
- The Krascendo 1 study evaluated investigational divarasib against current KRAS G12C inhibitors in non-small cell lung cancer patients.
- Divarasib lowered the risk of death by 44 percent compared with sotorasib or adagrasib.
- The median overall survival reached approximately 18 months for divarasib compared to 12 months for the control arm.
- Researchers presented the data at the European Society for Medical Oncology Congress and published them in a medical journal.
Covered by 4 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Timeline
First to report: Globenewswire_fr (); 4 articles from 3 outlets so far.
Who is covering this story
- Center (3): Globenewswire_fr, Seeking Alpha, Pharmabiz
Sources
- Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer — Globenewswire_fr (center, AI-estimated) ·
- Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer — Globenewswire_fr (center, AI-estimated) ·
- Eli Lilly reports promising lung cancer drug results — Seeking Alpha (center, AI-estimated) ·
- Roche's divarasib demonstrated best─in─class efficacy, advancing the standard of care in previously treated KRAS G12C─mutated lung cancer — Pharmabiz (center, AI-estimated) ·